Pictured: Office of Merck Research Laboratories in South San Francisco, California/iStock, hapabapa
Merck on Thursday launched a Phase III trial that will evaluate its oral KRAS inhibitor candidate MK-1084 in non-small cell lung cancer patients carrying the G12C mutation in the…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
